Sign In
Buy FDMT
$10.18
+0.110 (+1.09%)
At Close: Jul 31, 2026
4DMT Completes Enrollment for 4FRONT-1 Phase 3 Clinical Trial of 4D-150 in Wet AMD
08:00am, Monday, 09'th Feb 2026
Enrollment for 4FRONT-1, the first registrational trial for 4D-150 in wet AMD, was completed within an approximately 11-month period, ahead of initial projections 4FRONT-1 overenrolled and expected
4DMT Announces New Employment Inducement Grants
08:00am, Saturday, 17'th Jan 2026
EMERYVILLE, Calif., Jan. 17, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
01:35pm, Wednesday, 14'th Jan 2026
4D Molecular Therapeutics, Inc. (FDMT) Presents at 44th Annual J.P. Morgan Healthcare Conference Transcript
Contrasting NLS Pharmaceutics (NASDAQ:NCEL) and 4D Molecular Therapeutics (NASDAQ:FDMT)
02:04am, Saturday, 10'th Jan 2026
4D Molecular Therapeutics (NASDAQ: FDMT - Get Free Report) and NLS Pharmaceutics (NASDAQ: NCEL - Get Free Report) are both small-cap medical companies, but which is the better business? We will contra
4DMT Provides Company Update and Anticipated Development Milestones for 2026
08:00am, Wednesday, 07'th Jan 2026
EMERYVILLE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT, or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted
4D Molecular Therapeutics (NASDAQ:FDMT) Insider Sells $17,821.50 in Stock
05:19am, Monday, 22'nd Dec 2025
4D Molecular Therapeutics, Inc. (NASDAQ: FDMT - Get Free Report) insider Scott Bizily sold 1,635 shares of the business's stock in a transaction dated Tuesday, December 16th. The stock was sold at an
4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript
12:59pm, Wednesday, 17'th Dec 2025
4D Molecular Therapeutics, Inc. (FDMT) Discusses Interim Phase I Data From AEROW Trial in Cystic Fibrosis and Platform Potential Transcript
4DMT Announces Positive Interim Clinical Data from 4D-710 AEROW Phase 1 Clinical Trial in Cystic Fibrosis Lung Disease
07:00am, Wednesday, 17'th Dec 2025
Clinically meaningful lung function activity, measured by ppFEV 1 and LCI 2.5 , with follow-up through 1 year at dose selected for Phase 2 Durable CFTR transgene expression within target therapeutic
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 12'th Dec 2025
EMERYVILLE, Calif., Dec. 12, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4DMT to Present at the 44th Annual J.P. Morgan Healthcare Conference
08:00am, Monday, 08'th Dec 2025
EMERYVILLE, Calif., Dec. 08, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4D Molecular Therapeutics, Inc. (FDMT) Presents at Jefferies London Healthcare Conference 2025 Transcript
07:43pm, Friday, 21'st Nov 2025
4D Molecular Therapeutics, Inc. ( FDMT ) Jefferies London Healthcare Conference 2025 November 18, 2025 4:00 AM EST Company Participants David Kirn - Co-Founder, CEO & Director Christopher Simms - Chie
4DMT to Participate in 8th Annual Evercore Healthcare Conference
08:00am, Thursday, 20'th Nov 2025
EMERYVILLE, Calif., Nov. 20, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4DMT Appoints Kristian Humer as Chief Financial Officer
06:00am, Monday, 17'th Nov 2025
EMERYVILLE, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4DMT Announces New Employment Inducement Grants
04:05pm, Friday, 14'th Nov 2025
EMERYVILLE, Calif., Nov. 14, 2025 (GLOBE NEWSWIRE) -- 4D Molecular Therapeutics (Nasdaq: FDMT, 4DMT or the Company), a leading late-stage biotechnology company advancing durable and disease-targeted t
4D Molecular Therapeutics, Inc. (FDMT) Reports Q3 Loss, Lags Revenue Estimates
10:16am, Monday, 10'th Nov 2025
4D Molecular Therapeutics, Inc. (FDMT) came out with a quarterly loss of $1.01 per share versus the Zacks Consensus Estimate of a loss of $1.02. This compares to a loss of $0.79 per share a year ago.
